# Vincent Ossipow

> Vincent Ossipow is a Series A investor at Neomed Management backing Medical and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Neomed Management](https://shizune.co/investors/profile/neomed-management)
- Location: Geneva, Switzerland
- Total investments: 5
- Last investment: Mar 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/vincent-ossipow-b2a80b89/

Vincent Ossipow is a Series A investor at Neomed Management in Geneva focused on Medical and Health Care. Vincent Ossipow is based out of Geneva, Geneve and is the Partner of Omega Funds. Vincent previously worked at BioInvent as a Board Member. Vincent Ossipow attended the University of Geneva.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 40% |
| Health Care | 2 | 40% |
| Life Science | 2 | 40% |
| Biotechnology | 2 | 40% |
| Robotics | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 2 | 40% |
| United States | 2 | 40% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Callio Therapeutics | Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M | Series A | Mar 03, 2025 |  |
| Aerium Therapeutics | Aerium Therapeutics is discovering and developing novel monoclonal antibodies (mAbs) and antiviral treatments against SARS-CoV-2 variants. |  | Series A | Mar 22, 2022 |  |
| FoRx Therapeutics | FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $10.8M | Seed | Apr 22, 2020 |  |
| Andrew Alliance | Andrew Alliance S.A. is an independent Swiss company, privately financed, based in the canton of Geneva. The company has been created in March 2011 by a founding team that counts more than 100 years experience in the sector of instrumentation for the Life Sciences. The development of the underlying technology had started in 2010, with the purposeof commercializing easy to use robots to the benefit of the Life Science community. By integrating state-of-art robotics, innovative hardware solutions, camera-based vision and software algorithms, Andrew Alliance intends to provide a new generation of tools to biologists and technicians that – today – have no alternative to manual liquid handling operations.The Andrew Alliance products, Andrew ™ and Andrew Assistant ™, incorporate various technologies under the hood that make it possible to change the user experience without changing the process. Andrew Instruments are assembled and tested in Switzerland, where the service and support organization is based. The Andrew Alliance incorporation has been sponsored by VentureKick, critical R&D developments are financed through the EUREKA EUROSTARS programme, and the company has been awarded the CTI-startup label from the Swiss federation. | $14M | Series C | Jun 12, 2018 |  |
| Andrew Alliance | Andrew Alliance S.A. is an independent Swiss company, privately financed, based in the canton of Geneva. The company has been created in March 2011 by a founding team that counts more than 100 years experience in the sector of instrumentation for the Life Sciences. The development of the underlying technology had started in 2010, with the purposeof commercializing easy to use robots to the benefit of the Life Science community. By integrating state-of-art robotics, innovative hardware solutions, camera-based vision and software algorithms, Andrew Alliance intends to provide a new generation of tools to biologists and technicians that – today – have no alternative to manual liquid handling operations.The Andrew Alliance products, Andrew ™ and Andrew Assistant ™, incorporate various technologies under the hood that make it possible to change the user experience without changing the process. Andrew Instruments are assembled and tested in Switzerland, where the service and support organization is based. The Andrew Alliance incorporation has been sponsored by VentureKick, critical R&D developments are financed through the EUREKA EUROSTARS programme, and the company has been awarded the CTI-startup label from the Swiss federation. |  | Series B |  |  |

5 of 5 investments shown.

## Co-investors
- [Norwest](https://shizune.co/investors/profile/norwest-venture-partners) — VC Fund, 2 deals together
- [ClavystBio](https://shizune.co/investors/profile/clavystbio) — VC Fund, 1 deal together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 1 deal together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together
- [Frazier Life Sciences](https://shizune.co/investors/profile/frazier-life-sciences-fc2e) — VC Fund, 1 deal together
- [Inpeco](https://shizune.co/investors/profile/inpeco) — VC Fund, 1 deal together

## About Neomed Management

VC Fund · Oslo, Norway

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

5 contacts available at Neomed Management.

| Name | Title | Profile |
| --- | --- | --- |
| Erik Amble | Founder, Chairman & Managing Partner | https://shizune.co/investors/profile/erik-amble-8d03 |
| Thomas Goebel | Principal | https://shizune.co/investors/profile/thomas-goebel |
| Vincent Ossipow | Partner | https://shizune.co/investors/profile/vincent-ossipow |
| Claudio Nessi | Partner | https://shizune.co/investors/profile/claudio-nessi |
| Line B. Westlund | Office Manager | https://shizune.co/investors/profile/line-b-westlund |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Vincent Ossipow invest in?

Vincent Ossipow invests primarily in Medical, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Vincent Ossipow last invest?

The most recent investment recorded for Vincent Ossipow closed in Mar 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co